公开(公告)号：US09974804B1

公开(公告)日：2018-05-22

申请号：US15699422

申请日：2017-09-08

申请人： David Lloyd Smith

发明人： David Lloyd Smith

IPC分类号： A61K9/68 ,  A61K33/00 ,  A61K31/194 ,  A61K31/375 ,  A61K31/519 ,  A61K31/593 ,  A61K9/20 ,  A61K9/00 ,  A61Q11/00 ,  A61K8/19 ,  A61K8/365 ,  A61K8/67

CPC分类号： A61K33/00 ,  A61K8/19 ,  A61K8/365 ,  A61K8/67 ,  A61K8/673 ,  A61K8/676 ,  A61K9/0056 ,  A61K9/0058 ,  A61K9/006 ,  A61K9/0063 ,  A61K9/145 ,  A61K9/20 ,  A61K31/194 ,  A61K31/375 ,  A61K31/519 ,  A61K31/593 ,  A61K33/24 ,  A61Q11/00

摘要： A strontium-based composition for controlling progression of osteoarthritis, osteoporosis, and tooth decay is presented. The composition may include a blend of ingredients including: at least 500 mg of strontium carbonate; citric acid; ascorbic acid; malic acid; folic acid; vitamin d3; magnesium citrate; natural sweetener; and flavoring. The all-natural strontium-based blend of ingredients is simply delivered to the oral cavity where an “in-vivo” chemical reaction takes place resulting in direct tooth and dentin exposure to facilitate direct dental anti-caries and anti-sensitivity strontium benefits. The blend of ingredients is then swallowed to establish intestinal transit and absorption to obtain the targeted benefits of systemic absorption to bone and joint areas.